Abnormalities, Multiple: Clinical Trials

14 trials for Abnormalities, Multiple, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 withdrawn. 14 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 214Withdrawn 14
Phase 11Withdrawn 1
Phase 31Withdrawn 1

Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome
Sargramostim for Injection, Saline Placebo - Down Syndrome
Phase 2WithdrawnUniversity of Colorado, Denver2023-10-232025-04-02
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
NNZ-2591 - Prader-Willi Syndrome
Phase 2WithdrawnNeuren Pharmaceuticals Limited2023-09-012024-12-09
12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi
NFX-179 Gel 1.50% - Epidermal Nevi, Nevus Sebaceus
Phase 2WithdrawnAlbert Chiou2023-06-012024-05-28
Mitochondrial Complex I Dysfunction in PWS
Coenzyme Q10, Placebo - Prader-Willi Syndrome
Phase 2WithdrawnThe Hospital for Sick Children2023-06-012024-06-18
Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome
Placebo, Tesomet - Prader-Willi Syndrome
Phase 2WithdrawnSaniona2021-12-282022-12-13
A Study of ACI-24 in Adults With Down Syndrome
ACI-24, Placebo - Down Syndrome
Phase 2WithdrawnAC Immune SA2021-10-012021-10-22
tVNS in Children With Prader-Willi Syndrome
tVNS - Prader-Willi Syndrome, Social Behavior
Phase 1 / Phase 2WithdrawnStanford University2020-07-012021-05-06
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Vismodegib, Nivolumab, Ipilimumab - Basal Cell Nevus Syndrome
Phase 2WithdrawnColumbia University2019-07-012019-12-18
Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement
Metformin - Bardet-Biedl Syndrome, Visual Impairment
Phase 2WithdrawnUniversity Hospital Tuebingen2018-04-012019-04-18
A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)
Diazoxide choline controlled-release tablet - Prader-Willi Syndrome
Phase 2WithdrawnEssentialis, Inc.2017-07-012026-11-17
An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
EPI-743 - Autism Spectrum Disorder
Phase 2WithdrawnEdison Pharmaceuticals Inc2014-10-312022-01-21
Novel Treatment for Syndromic Ichthyoses
Lovastatin - Syndromic Ichthyoses, CHILD Syndrome
Phase 2WithdrawnNorthwestern University2011-07-012015-05-19
Liq-NOL Efficacy in Pediatric Patients With Down Syndrome
Ubiquinol-10 Syrup, syrup (placebo) - Down Syndrome
Phase 2WithdrawnChildren's Hospital Medical Center, Cincinnati2005-01-012020-09-09
Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
LDE225B, Vehicle - Basal Cell Carcinoma
Phase 2 / Phase 3WithdrawnNovartis Pharmaceuticals2017-05-05

Narrower conditions

Prader-Willi Syndrome (5)  ·  Down Syndrome (3)  ·  Basal Cell Nevus Syndrome (2)  ·  Angelman Syndrome (1)  ·  Autism Spectrum Disorder (1)  ·  Autistic Disorder (1)  ·  Bardet-Biedl Syndrome (1)  ·  Behavior (1)  ·  Carcinoma, Basal Cell (1)  ·  Cognitive Dysfunction (1)  ·  Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects (1)  ·  Hyperphagia (1)  ·  Language (1)  ·  Mitochondrial Diseases (1)  ·  Nevus, Sebaceous of Jadassohn (1)

Broader conditions

Congenital Abnormalities (14)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14)  ·  Genetic Diseases, Inborn (13)  ·  Nervous System Diseases (11)  ·  Neurologic Manifestations (10)  ·  Chromosome Disorders (9)  ·  Intellectual Disability (9)  ·  Neurobehavioral Manifestations (9)  ·  Nutritional and Metabolic Diseases (7)  ·  Imprinting Disorders (6)  ·  Nutrition Disorders (5)  ·  Obesity (5)  ·  Overnutrition (5)  ·  Overweight (5)

Interventions

Granulocyte-Macrophage Colony-Stimulating Factor (1)  ·  HhAntag691 (1)  ·  Injections (1)  ·  Ipilimumab (1)  ·  Lovastatin (1)  ·  Metformin (1)  ·  Metoprolol (1)  ·  Nivolumab (1)  ·  Tesofensine (1)  ·  alpha-tocotrienol quinone (1)  ·  coenzyme Q10 (1)  ·  cyclo-L-glycyl-L-2-allylproline (1)  ·  sargramostim (1)

Sponsors

AC Immune SA (1)  ·  Albert Chiou (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Columbia University (1)  ·  Edison Pharmaceuticals Inc (1)  ·  Essentialis, Inc. (1)  ·  Neuren Pharmaceuticals Limited (1)  ·  Northwestern University (1)  ·  Novartis Pharmaceuticals (1)  ·  Saniona (1)  ·  Stanford University (1)  ·  The Hospital for Sick Children (1)  ·  University Hospital Tuebingen (1)  ·  University of Colorado, Denver (1)

Countries

United States (5)  ·  Canada (2)  ·  Belgium (1)  ·  Czechia (1)  ·  Finland (1)  ·  Germany (1)  ·  Greece (1)  ·  Italy (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Albert S Chiou, MD, MBA (1)  ·  Amy S Paller, MD (1)  ·  Francis Hickey, M.D. (1)  ·  Heiko Billing, PD Dr. med. (1)  ·  Ingrid Tein, MD (1)  ·  Jordan Press (1)  ·  Michael S. Rafii, MD, PhD (1)  ·  Michael V Miles, Pharm.D. (1)  ·  Peter Pressman, MD (1)  ·  Richard Carvajal, MD. (1)  ·  Sophie Guillaume, MS (1)

Results publications

PMID 33778150, PMID 35307513

NIH funding

R61AG074859 (1)